Pictet Asset Management Holding SA Takes Position in Savara Inc. $SVRA

Pictet Asset Management Holding SA acquired a new position in shares of Savara Inc. (NASDAQ:SVRA) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,275,381 shares of the company’s stock, valued at approximately $12,424,000. Pictet Asset Management Holding SA owned about 1.11% of Savara at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Osaic Holdings Inc. lifted its stake in Savara by 6.9% in the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock valued at $197,000 after purchasing an additional 2,098 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Savara by 3.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock valued at $420,000 after buying an additional 2,116 shares during the period. Graham Capital Management L.P. raised its stake in Savara by 4.9% in the fourth quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after buying an additional 2,615 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Savara by 9.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock valued at $200,000 after buying an additional 2,859 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Savara by 48.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after buying an additional 3,205 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Trading Up 2.6%

Shares of SVRA stock opened at $6.22 on Friday. Savara Inc. has a 12-month low of $2.10 and a 12-month high of $7.01. The company has a market capitalization of $1.27 billion, a PE ratio of -11.11 and a beta of 0.24. The firm has a 50 day moving average price of $5.30 and a two-hundred day moving average price of $5.56. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, analysts predict that Savara Inc. will post -0.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SVRA shares. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Oppenheimer assumed coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a research report on Monday, March 16th. Finally, William Blair set a $10.00 price objective on shares of Savara in a report on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.